Last kr187.50 SEK
Change Today +2.00 / 1.08%
Volume 1.8K
BIOGB On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Stockholm
OTC US
As of 11:30 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

biogaia ab-b shs (BIOGB) Snapshot

Open
kr185.50
Previous Close
kr185.50
Day High
kr190.00
Day Low
kr185.50
52 Week High
09/11/13 - kr252.41
52 Week Low
04/11/14 - kr165.00
Market Cap
3.2B
Average Volume 10 Days
8.0K
EPS TTM
kr8.23
Shares Outstanding
16.5M
EX-Date
05/7/14
P/E TM
22.8x
Dividend
kr3.35
Dividend Yield
3.73%
Current Stock Chart for BIOGAIA AB-B SHS (BIOGB)

Related News

No related news articles were found.

biogaia ab-b shs (BIOGB) Related Businessweek News

No Related Businessweek News Found

biogaia ab-b shs (BIOGB) Details

BioGaia AB develops, markets, and sells probiotic products with documented health benefits worldwide. The company operates through Finished Consumer Products, Component Products, and Other Products segments. It offers products for the treatment of acute diarrhoea, constipation, helicobacter pylori infection, infant colic, regurgitation, and gingivitis, as well as for digestive and oral health. The company provides BioGaia ProTectis digestive health probiotic drops, as well as BioGaia ProTectis D3 drops with vitamin D3 containing lactobacillus reuteri protectis for children; and BioGaia ProTectis ORS, a probiotic oral rehydration solution with zinc. It also offers BioGaia ProTectis chewable tablet, a dietary supplement containing lactobacillus reuteri protectis, as well as BioGaia ProDentis oral lozenges, a dietary supplement containing lactobacillus reuteri prodentis for adults and children; BioGaia Gastrus, a probiotic supplement that could enhance treatment of Helicobacter pylori infection; and BioGaia ProTectis straw that provides lactobacillus reuteri protectis to various beverages. In addition, the company offers ProDentis oral health tablet for the treatment of periodontal disease and gingivitis; and component products, which are bacterial cultures of lactobacillus reuteri protectis that are used as ingredients in infant formula and cereal products, yoghurt, and other dairy products. Further, it provides animal health products. The company sells its products through pharmacies and related outlets. BioGaia AB was founded in 1990 and is headquartered in Stockholm, Sweden.

88 Employees
Last Reported Date: 05/6/14
Founded in 1990

biogaia ab-b shs (BIOGB) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2012.

biogaia ab-b shs (BIOGB) Key Developments

BioGaia Signs New Exclusive Agreement with Nestle Nutrition

BioGaia has extended its global contract with Nestle Nutrition by signing an agreement with the company’s UK infant nutrition business for the exclusive rights to sell BioGaia’s ProTectis Baby Drops in the United Kingdom and Ireland. Launch is planned to take place in the beginning of 2015. Nestle Nutrition UK will market both BioGaia ProTectis Baby Drops, which is BioGaia's biggest product, and BioGaia ProTectis Baby Drops with vitamin D. Both products contain BioGaia's patented and well-documented probiotic strain Lactobacillus reuteri Protectis.

BioGaia Signs Non-Exclusive Agreement with Pharma Base SA

BioGaia has signed a non-exclusive agreement with Pharma Base SA for the rights to sell BioGaia's ProTectis Baby Drops in India. Pharma Base will cooperate with a local distributor for the marketing and sales of the drops, which will be sold under BioGaia's own brand. The registration of the product will start 2014 and the launch is planned to the beginning of 2015. Marketing of the BioGaia drops will be focused on the Mumbai region and in the state of Maharashtra.

BioGaia AB Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2014

BioGaia AB reported consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company’s net sales amounted to SEK 93,218,000 against SEK 78,142,000 a year ago. Operating profit was SEK 123,779,000 against SEK 17,754,000 a year ago. Profit before tax was SEK 124,656,000 against SEK 22,703,000 of prior year period. Profit for the period was SEK 96,967,000 against SEK 17,677,000 a year ago. Profit attributable to owners of the parent company was SEK 97,207,000 against SEK 16,709,000 a year ago. Basic and diluted earnings per share were SEK 5.63 against SEK 0.97 a year ago. Cash flow from operating activities was SEK 112,778,000 against SEK 78,441,000 a year ago. Return on average equity was 27% against 4% a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOGB:SS kr187.50 SEK +2.00

BIOGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BLIS Technologies Ltd $0.02 NZD +0.001
Danone SA €55.06 EUR -0.92
Oragenics Inc $1.87 USD -0.075
Probi AB kr47.00 SEK -0.60
Yakult Honsha Co Ltd ¥5,390 JPY +130.00
View Industry Companies
 

Industry Analysis

BIOGB

Industry Average

Valuation BIOGB Industry Range
Price/Earnings 21.4x
Price/Sales 7.1x
Price/Book 7.3x
Price/Cash Flow 20.4x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGAIA AB-B SHS, please visit www.biogaia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.